← Leaderboards

Siobhan Malany

Mayo Clinic Rochester

Google Scholar ↗PubMed ↗ORCID ↗

$5,060,787

Attributed

$9,848,415

Total exposure

6

Grants

3

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.5M · FY2017–25

$2M$1.5M$1M$500K$0

'17

'18

'19

'20

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$9,848,415 · 6

By mechanism

R01$7,402,320 · 3

UH3$1,031,461 · 1

UG3$1,026,796 · 1

R21$387,838 · 1

Top collaborators

Most similar at Mayo Clinic Rochester

Same institution · by research overlap

Others in their field

Other Emerging Leaders on “United States National Institutes Of Health”

Leonard Freedman · Leidos Biomedical Research, Inc.$816,847,401
Sonia M Thomas · Research Triangle Institute$701,865,642
Bambra Strokes · Ppd Development Lp$526,656,217
Tracy L Nolen · Research Triangle Institute$474,487,152
Chanza Baytop · Westat, Inc.$271,217,917
Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$250,731,514

Research focus

United States National Institutes Of HealthPathway InteractionsNovel TherapeuticsIn VitroMediatingPharmaceutical ChemistryBiologicalSmall MoleculeCellsLeadPharmaceutical PreparationsFda ApprovedClinically RelevantSmall Molecule TherapeuticsLead OptimizationDrug KineticsPropertyIn VivoInflammationDesignDrug DiscoveryGene ExpressionAreaMeasurement

Grant awards (21)

Novel Therapeutics for Cardiovascular Disease$681,486

R01 · FY2025 · HL

Novel Therapeutics for Cardiovascular Disease$672,130

R01 · FY2024 · HL

Advancing small molecule CXCR4 agonists for diabetic wound healing$273,660

R01 · FY2024 · DK

Novel Therapeutics for Cardiovascular Disease$693,407

R01 · FY2023 · HL

Advancing small molecule CXCR4 agonists for diabetic wound healing$469,894

R01 · FY2023 · DK

Preclinical development of CXCR6 antagonists to target sorafenib resistance in Hepatocellular Carcinoma$209,604

R21 · FY2023 · CA · contact PI

Novel Therapeutics for Cardiovascular Disease$715,647

R01 · FY2022 · HL

Advancing small molecule CXCR4 agonists for diabetic wound healing$406,930

R01 · FY2022 · DK

Advancing small molecule CXCR4 agonists for diabetic wound healing$239,216

R01 · FY2022 · DK

Preclinical development of CXCR6 antagonists to target sorafenib resistance in Hepatocellular Carcinoma$178,234

R21 · FY2022 · CA · contact PI

Advancing small molecule CXCR4 agonists for diabetic wound healing$633,559

R01 · FY2021 · DK

Electrical Stimulation of Human Myocytes in Microgravity: An In Vitro Model to Evaluate Therapeutics to Counteract Muscle Wasting$483,238

UH3 · FY2021 · TR · contact PI

Deposition of data from ground and flight samples for sarcopenia MPS system$76,250

UH3 · FY2021 · TR · contact PI

Advancing small molecule CXCR4 agonists for diabetic wound healing$607,029

R01 · FY2020 · DK

Electrical Stimulation of Human Myocytes in Microgravity: An In Vitro Model to Evaluate Therapeutics to Counteract Muscle Wasting$471,973

UH3 · FY2020 · TR · contact PI

Small Molecule Discovery for Particulate Guanylyl Cyclase Receptor B Enhancers$651,411

R01 · FY2019 · AG

Electrical Stimulation of Human Myocytes in Microgravity: An In Vitro Model to Evaluate Therapeutics to Counteract Muscle Wasting$484,664

UG3 · FY2019 · TR · contact PI

Small Molecule Discovery for Particulate Guanylyl Cyclase Receptor B Enhancers$712,741

R01 · FY2018 · AG

Electrical Stimulation of Human Myocytes in Microgravity: An In Vitro Model to Evaluate Therapeutics to Counteract Muscle Wasting$502,561

UG3 · FY2018 · TR · contact PI

Electrical Stimulation of Human Myocytes in Microgravity: An In Vitro Model to Evaluate Therapeutics to Counteract Muscle Wasting$39,571

UG3 · FY2018 · TR · contact PI

Small Molecule Discovery for Particulate Guanylyl Cyclase Receptor B Enhancers$645,210

R01 · FY2017 · AG